Supernus Pharmaceuticals Stock Today
| SUPN Stock | USD 29.71 0.31 1.05% |
Performance3 of 100
| Odds Of DistressLess than 6
|
Supernus Pharmaceuticals is selling at 29.71 as of the 23rd of April 2024; that is 1.05% increase since the beginning of the trading day. The stock's open price was 29.4. Supernus Pharmaceuticals has only a 6 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Supernus Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of March 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of May 2012 | Category Healthcare | Classification Health Care |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. The company has 54.73 M outstanding shares of which 4.82 M shares are at this time shorted by private and institutional investors with about 9.64 trading days to cover. More on Supernus Pharmaceuticals
Moving together with Supernus Stock
| 0.89 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.83 | ERNA | Eterna Therapeutics | PairCorr |
| 0.76 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Moving against Supernus Stock
| 0.43 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Supernus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Supernus Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Supernus Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Jack Khattar | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Trump Equities, Obamacare Repeal, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Supernus Pharmaceuticals report their recommendations after researching Supernus Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Supernus Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Supernus Pharmaceuticals. The Supernus consensus assessment is calculated by taking the average forecast from all of the analysts covering Supernus Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Supernus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Supernus Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. Financial strength of Supernus Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Supernus Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Supernus Pharmaceuticals' financial leverage. It provides some insight into what part of Supernus Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Pharmaceuticals (SUPN) is traded on NASDAQ Exchange in USA. It is located in 9715 Key West Avenue, Rockville, MD, United States, 20850 and employs 652 people. Supernus Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.61 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Supernus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Supernus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Supernus Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 54.73 M outstanding shares of which 4.82 M shares are at this time shorted by private and institutional investors with about 9.64 trading days to cover.
Supernus Pharmaceuticals currently holds about 360.79 M in cash with 111.08 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.74.
Check Supernus Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationSupernus Pharmaceuticals maintains a total of 54.73 Million outstanding shares. The majority of Supernus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Supernus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Supernus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Supernus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Supernus Ownership Details
Supernus Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Supernus Pharmaceuticals jumping above the current price in 90 days from now is about 61.31%. The Supernus Pharmaceuticals probability density function shows the probability of Supernus Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.1237. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Supernus Pharmaceuticals will likely underperform. Additionally, supernus Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Supernus Pharmaceuticals to move above the current price in 90 days from now is about 61.31 (This Supernus Pharmaceuticals probability density function shows the probability of Supernus Stock to fall within a particular range of prices over 90 days) .
Supernus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Supernus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Supernus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Supernus Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 0006-10-31 | 1.2 M | |
| Aristotle Capital Boston, Llc | 2023-12-31 | 1.2 M | |
| Pictet Asset Manangement Sa | 2023-12-31 | 1 M | |
| Congress Asset Management Company, Llp | 2024-03-31 | 1 M | |
| Ashford Capital Management Inc | 2023-12-31 | 826.5 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 723.4 K | |
| Victory Capital Management Inc. | 2023-12-31 | 690.4 K | |
| Northern Trust Corp | 2023-12-31 | 648.4 K | |
| Ameriprise Financial Inc | 559.7 K | ||
| Blackrock Inc | 2023-12-31 | 10.4 M | |
| Vanguard Group Inc | 2023-12-31 | 6.2 M |
Supernus Pharmaceuticals Historical Income Statement
Supernus Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Supernus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Supernus Pharmaceuticals revenue and expense. Supernus Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Supernus Pharmaceuticals' Non Operating Income Net Other is very stable compared to the past year. As of the 23rd of April 2024, Tax Provision is likely to grow to about 17.1 M, while Interest Expense is likely to drop about 2.3 M. View More FundamentalsSupernus Stock Against Markets
Picking the right benchmark for Supernus Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Supernus Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Supernus Pharmaceuticals is critical whether you are bullish or bearish towards Supernus Pharmaceuticals at a given time. Please also check how Supernus Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Supernus Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Supernus Pharmaceuticals Corporate Directors
Supernus Pharmaceuticals corporate directors refer to members of a Supernus Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Supernus Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Supernus Pharmaceuticals' board members must vote for the resolution. The Supernus Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Charles Newhall | Independent Director | Profile | |
| John Siebert | Independent Director | Profile | |
| Georges Gemayel | Independent Director | Profile | |
| Frederick Hudson | Independent Director | Profile |
How to buy Supernus Stock?
Before investing in Supernus Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Supernus Pharmaceuticals. To buy Supernus Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Supernus Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Supernus Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Supernus Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Supernus Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Supernus Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Supernus Stock please use our How to Invest in Supernus Pharmaceuticals guide.
Already Invested in Supernus Pharmaceuticals?
The danger of trading Supernus Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Supernus Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Supernus Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Supernus Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.